行情

MCRB

MCRB

Seres
NASDAQ

实时行情|Nasdaq Last Sale

3.310
-0.210
-5.97%
交易中 13:50 01/24 EST
开盘
3.510
昨收
3.520
最高
3.550
最低
3.260
成交量
13.25万
成交额
--
52周最高
8.39
52周最低
2.020
市值
2.32亿
市盈率(TTM)
-2.0860
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MCRB 新闻

  • 波音据悉将考虑再度削减波音787梦想客机的产量
  • 新浪美股.34分钟前
  • 沃尔玛据悉在美国门店测试提高新岗位员工起薪
  • 新浪美股.39分钟前
  • 欧元区PMI数据提供支撑 欧股上扬
  • FX168.41分钟前
  • 午盘:制造业PMI不及预期 美股下跌道指跌近100点
  • 新浪美股.1小时前

更多

所属板块

生物技术和医学研究
-2.40%
制药与医学研究
-1.73%

热门股票

名称
价格
涨跌幅

MCRB 简况

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.
展开

Webull提供Seres Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。